Study on COVID-19 and RMD provides reassurance to patients on immunosuppressive medication

A current study published in the run-up to the European Congress of Rheumatology of the EULAR (European League Against Rheumatism) analysed, for the first time, 600 COVID-19 cases in rheumatic disease patients from 40 countries and investigated the impact of the choice of rheumatic disease therapy on potential hospitalization and the course of COVID-19. The results of the study will be presented in an online press conference in the context of the EULAR Congress on June 3, 2020.